Publications

Abstract BACKGROUND & AIMS Alcohol is a key driver of liver-related mortality, and phosphatidylethanol (PEth) is a direct biomarker of alcohol intake. We investigated the prognostic performance of PEth with noninvasive liver fibrosis tests (NITs) for predicting hepatic decompensation in an alcohol-related liver disease (ALD) at-risk population. METHODS Prospective cohort study with 411 at risk […]

Go to full publication

Go to full publication

Abstract RATIONALE LAM is a rare cystic lung disease driven by nodules containing “LAM cells” and recruited LAM associated fibroblasts. Although rapamycin reduces lung function loss, some patients continue to decline, meaning additional therapies are needed. OBJECTIVES To investigate how the LAM nodule environment affects LAM cell proliferation and the response to rapamycin. METHODS Proteins […]

Abstract Endotrophin, a biologically active fragment derived from the α3 chain of collagen type VI, has emerged as both a risk biomarker and a potential pathogenic factor in Cardiovascular-Kidney-Metabolic (CKM) syndrome. Over the past decade, research has shed light on its role in various non-communicable diseases, emphasizing its signaling properties and diagnostic potential. Despite these […]

Abstract BACKGROUND & AIMS The role of antibody-mediated rejection (AMR) after liver transplantation (LT) remains controversial. Chronic AMR (cAMR) is often subclinical and may be missed without surveillance biopsies (svLbx). Transcriptome analyses have previously characterized molecular changes in T cell-mediated rejection (TCMR) after solid organ transplantation. We aimed to identify molecular signatures of cAMR after […]

Abstract Psoriatic disease (PsD) is a complex, heterogeneous disease with unmet medical needs in terms of its diagnosis, management, and prognosis. The identification of biomarkers could improve the implementation of precision medicine in PsD, but to date, none of these biomarkers have been clinically validated. Biomarkers can support clinical trials in several ways, including (1) […]

Abstract OBJECTIVE The Foundation for National Institutes of Health (FNIH) OA Biomarkers Consortium aims to identify and qualify biomarkers to support drug development in knee osteoarthritis (OA). The PROGRESS OA study aims to externally validate prognostic biomarkers identified in the earlier Phase I study. DESIGN PROGRESS OA included data from the control arms of several […]

Abstract OBJECTIVE The Foundation for National Institutes of Health (FNIH) OA Biomarkers Consortium aims to identify and qualify biomarkers to support drug development in knee osteoarthritis (OA). The PROGRESS OA study aims to externally validate prognostic biomarkers identified in the earlier Phase I study. DESIGN PROGRESS OA included data from the control arms of several […]

Abstract OBJECTIVE The Foundation for National Institutes of Health (FNIH) OA Biomarkers Consortium aims to identify and qualify biomarkers to support drug development in knee osteoarthritis (OA). The PROGRESS OA study aims to externally validate prognostic biomarkers identified in the earlier Phase I study. DESIGN PROGRESS OA included data from the control arms of several […]